NRX Pharmaceuticals, headquartered in Wilmington, Delaware, is a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, including its lead compounds NRX-100 and NRX-101. The company went public on November 20, 2017, and is developing therapies targeting bipolar depression, chronic pain, and PTSD.
NRX Pharmaceuticals (NRXP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, NRX Pharmaceuticals's actual EPS was -$0.21, beating the estimate of -$0.31 per share, resulting in a 31.37% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
